David J. Arthur - 03 Mar 2022 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
03 Mar 2022
Net transactions value
+$54,540
Form type
4
Filing time
09 Mar 2022, 15:01:55 UTC
Previous filing
21 Jan 2022
Next filing
05 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Purchase $54,540 +139,488 +127% $0.3910 249,674 03 Mar 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Registrant issued these shares to the reporting person as part of his bonus; which shares were issued in lieu of net cash compensation. The shares were issued at the fair market value of the Registrants common stock on the date of grant.